Mumbai: Amidst the
ongoing news of conventional insulin market disruption and growing concern over potential
shortages triggered by Novo Nordisk’s decision to withdraw key human insulin
products in India, Indian pharmaceutical companies are stepping in to stabilize
supply, ensure accessibility and reassure patients.

Medical Dialogues had earlier reported that
Novo Nordisk is phasing out several pen-fill and cartridge-based insulin
formulations — including its popular brand Mixtard, as part of its global portfolio restructuring. Also Read: As Ozempic, Wegovy Take Priority, Novo Nordisk Winds Down Insulin Portfolio In IndiaThe move has spelt out
a direct commercial impact for Abbott India, which has been marketing several
of these insulin products in the country.
With the pen-fill and cartridge formats being phased out, Abbott faces a narrowing of its insulin portfolio at a
time when demand for convenient delivery systems remains high.

Amidst the fear of
disruption in supply and accessibility, Indian pharmaceutical companies have
stepped up to assure continuity of care. Speaking to the Medical Dialogues team, officials from Lupin, the second-largest
player in India’s human insulin market*
affirmed that their insulin brand — Huminsulin — remains fully available across
formats.Gagan Arora, Vice
President – Lupin Metabolic, told Medical
Dialogues, “At Lupin, patient access and uninterrupted supply are
top priorities, especially for underserved.. Our insulin products are available pan-India in both vial and
cartridge forms. Even if there are shifts in prescribing patterns due to recent
market developments, we are well prepared to ensure seamless availability and
any increase in demand. With the help of healthcare providers and the supply chain stakeholders across the country we will support all patients through this transition.”

According to IQVIA
(MAT March 2025), Lupin’s Huminsulin is the second-largest human insulin brand
in India showing Lupin’s consistent presence and growing acceptance among
healthcare providers. The company had formally acquired Huminsulin from Eli
Lilly and Company in December 2024, further consolidating its position in the
diabetes care segment.

Premix insulins, such
as biphasic human insulin (30/70), play an important role in managing blood
glucose by addressing both fasting and postprandial spikes. Prefilled insulin
pens, such as those available for Huminsulin, are generally considered more user-friendly, economical and may support better adherence, particularly among elderly patients or those
initiated on insulin therapy.*According to IQVIA (MAT March 2025),